Value
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.0 |
| P/S | 5.4 |
| EV/EBITDA | 2.1 |
| Fwd P/E | 7.3 |
| PEG | 8.6 |
| Analyst target | 3.0 |
- ▸Forward P/E: 17.0x
- ▸PEG: 0.73
EXEL · Why this verdict
Why Exelixis (EXEL) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.2/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Exelixis is a wide-moat, high-quality biotech with 44% return on equity and 35% margins, but the price is 25% above the analyst target, RSI is 86, and the business depends on cabozantinib.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Exelixis earns an excellent 44% return on equity with 35% margins and a Piotroski F-Score of 9 out of 9. Quality breakdown | Return on equity stays above 30% and margins above 30% over the next 12 months. | →Stable |
| CounterReturns this high rest on one drug franchise, so a patent or competitive shock would collapse them. | ||
The company has a wide economic moat and best-in-class margins versus peers. Peer-rank breakdown | Margins stay at the top of the peer group over the next 12 months. | →Stable |
| CounterBiotech moats rest on patents that expire, and a moat described as wide today can be gone within a patent cycle. | ||
The business is concentrated in a single product, cabozantinib. Bear case | Cabozantinib sales keep growing while pipeline products diversify revenue. | ↓Deteriorating |
| CounterConcentration in a proven blockbuster is a smaller risk than an unproven pipeline, and the drug is still expanding in new indications. | ||
The $69.39 price is above the $52.01 analyst target, about 25.0% over it, against 15.0% downside to the stop. Warnings | Analysts raise targets above $65 or the price retraces toward the target. | ↓Deteriorating |
| CounterTargets lag price in strong rallies, and positive news sentiment of +0.73 could prompt a wave of upgrades. | ||
The stock is overbought with an RSI of 86, sits within 3.8% of its 52-week high, and has 15% short interest. Momentum breakdown | The price consolidates above its 200-day average with short interest declining. | ↑Improving |
| CounterA volume surge of 2.1 times average on an up move shows strong demand, and short covering could extend the rally. | ||
Exelixis earns an excellent 44% return on equity with 35% margins and a Piotroski F-Score of 9 out of 9.
→StableQuality breakdown
- Expectation
- Return on equity stays above 30% and margins above 30% over the next 12 months.
CounterReturns this high rest on one drug franchise, so a patent or competitive shock would collapse them.
The company has a wide economic moat and best-in-class margins versus peers.
→StablePeer-rank breakdown
- Expectation
- Margins stay at the top of the peer group over the next 12 months.
CounterBiotech moats rest on patents that expire, and a moat described as wide today can be gone within a patent cycle.
The business is concentrated in a single product, cabozantinib.
↓DeterioratingBear case
- Expectation
- Cabozantinib sales keep growing while pipeline products diversify revenue.
CounterConcentration in a proven blockbuster is a smaller risk than an unproven pipeline, and the drug is still expanding in new indications.
The $69.39 price is above the $52.01 analyst target, about 25.0% over it, against 15.0% downside to the stop.
↓DeterioratingWarnings
- Expectation
- Analysts raise targets above $65 or the price retraces toward the target.
CounterTargets lag price in strong rallies, and positive news sentiment of +0.73 could prompt a wave of upgrades.
The stock is overbought with an RSI of 86, sits within 3.8% of its 52-week high, and has 15% short interest.
↑ImprovingMomentum breakdown
- Expectation
- The price consolidates above its 200-day average with short interest declining.
CounterA volume surge of 2.1 times average on an up move shows strong demand, and short covering could extend the rally.
Per-dimension breakdown
Quality
9.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.8 |
| FCF quality | 6.3 |
| Moat | 9.0 |
| Rule of 40 | 7.1 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 44%
- ▸Strong margins: 35%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
5.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.0 |
| EPS growth | 6.6 |
Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.1 |
- ▸Overbought (RSI 89)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.2 |
| Analyst rating | 7.2 |
| Price target | 2.8 |
- ▸Below analyst target
Insider
4.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 3.9 |
| notable moves | 3.0 |
- ▸Negligible insider selling — $526,512 (0.003% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.4 |
| quality rank | 8.9 |
| growth rank | 4.2 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 9.8 |
| gap | 5.0 |
Risk (lower is worse)
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 0.0 |
| volatility | 5.6 |
| put call | 7.4 |
| implied vol | 6.4 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.6 |
- ▸Short squeeze setup: 15% short, quality 7.5
- ▸Above max pain $25
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 7.5 |
| news activity | 6.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Downgraded from BUY WAIT — price $72.75 vs the analyst target $53.38: -26.6% upside; No upside left.
Engine technical detail
verdict_path:
L4:PATH_E_WIDE_MOAT|SANITY:BUY+upside<=0Passed (5)
- MOMENTUM:7.3>=5.5
- INSIDER:OK
- EARNINGS_PROXIMITY:96d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.8=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.77
Upside
-26.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the ASYMMETRY gate's -1.8=NEGATIVE outcome against Quality at 9.2 and asymmetric R:R of -1.77.
The strongest dimensions are Quality at 9.2, Momentum at 7.3, and Catalyst at 6.7; the weakest are Technical at 3.8, Insider at 4.0, and Sentiment at 5.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.77 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Profitability And Returns
Trip ifReturn on equity falls below 25% from the current 44%.
- P2Wide Economic Moat
Trip ifNet margin falls below 25% from the current 35%.
- P3Cabozantinib Product Concentration
Trip ifCabozantinib share of revenue exceeds 90% from a high current concentration.
- P4Price Far Above Analyst Target
Trip ifPrice exceeds the analyst target by more than 40% from the current 25.0%.
- P5Overbought With Short Interest
Trip ifPrice drops to below the $55.77 stop level from the current $69.39.